Alto Neuroscience class action lawsuit filed by Pomerantz LLP.

A class action lawsuit has been filed against Alto Neuroscience, Inc. and certain officers over allegations of securities fraud related to the company's initial public offering and subsequent stock sales. The lawsuit claims that the defendants misrepresented the company's financial condition and prospects to investors, causing them to purchase securities at artificially inflated prices. The class action seeks damages on behalf of investors who purchased Alto securities during the relevant time period.

A class action lawsuit has been filed against Alto Neuroscience, Inc. (NYSE: ANRO) and certain officers, alleging securities fraud related to the company's initial public offering (IPO) and subsequent stock sales. The lawsuit claims that the defendants misrepresented the company's financial condition and prospects to investors, causing them to purchase securities at artificially inflated prices. The class action seeks damages on behalf of investors who purchased Alto securities during the relevant time period.

According to the lawsuit, filed by Rosen Law Firm [1], defendants made materially false and misleading statements regarding Alto's business, operations, and prospects. Specifically, the offering documents and defendants made false and/or misleading statements and/or failed to disclose that:

1. ALTO-100 was less effective in treating major depressive disorder (MDD) than defendants had led investors to believe.
2. Accordingly, ALTO-100's clinical, regulatory, and commercial prospects were overstated.
3. As a result, Alto's business and/or financial prospects were overstated.
4. As a result, Alto's public statements were materially false and misleading at all relevant times.

The lawsuit alleges that when the true details entered the market, investors suffered damages.

Investors who purchased Alto securities between February 2, 2024, and October 22, 2024, are eligible to join the class action. To join the Alto class action, go to [https://rosenlegal.com/submit-form/?case_id=42321](https://rosenlegal.com/submit-form/?case_id=42321) or contact Phillip Kim, Esq. at 866-767-3653 or email case@rosenlegal.com for more information. The deadline to move the Court for lead plaintiff appointment is September 19, 2025.

Another law firm, Levi & Korsinsky, LLP [2], has also notified investors about the class action lawsuit. Investors can contact Joseph E. Levi, Esq., via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500 for more information.

References:

[1] https://www.marketscreener.com/news/anro-investors-have-opportunity-to-lead-alto-neuroscience-inc-securities-fraud-lawsuit-ce7c51d9dc8ff527
[2] https://www.morningstar.com/news/globe-newswire/9512137/investors-who-lost-money-on-alto-neuroscience-inc-anro-should-contact-levi-korsinsky-about-pending-class-action-anro